InvestSMART

Argenica Therapeutics Limited (ASX:AGN)

ALERT: Price-sensitive ASX Announcement for AGN
Current share price for AGN : $0.140 -0.01 (-6.67%)+
Announcement
Release
14 May 2026 9:15AM
Price at Release
$0.150
Full Release
download
Summary
Argenica Therapeutics Limited announced the formation of a Clinical Advisory Committee to aid in the advancement of the Phase 2b clinical trial for their lead drug candidate, ARG-007, intended to treat acute ischaemic stroke. The committee comprises world-renowned experts in stroke neurology and related fields to enhance patient selection, dosing strategies, and overall trial design, aimed at maximizing the potential for clinical success. Dr. Mark Etherton, notable for his expertise in neuroprotection trials, will support the committee. This initiative is a strategic step towards optimizing the development and success of ARG-007.
Key Points
  • Argenica Therapeutics Limited establishes a Clinical Advisory Committee for Phase 2b trial.
  • Committee comprises internationally recognized stroke and neurology experts.
  • The focus is on advancing ARG-007 for acute ischaemic stroke treatment.
  • The committee will optimize trial design, including patient selection and dosing strategy.
  • Dr. Mark Etherton, an expert in stroke trials, supports the committee.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.